Overview

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-09-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Bevacizumab
Folfox protocol